Under the agreement, Pulsenmore and Clalit will establish an end-to-end clinical service operated through Beilinson NEXT, Beilinson Medical Center’s virtual hospital, enabling eligible patients to perform follicular monitoring scans from home with real-time online guidance and specialist clinical oversight. The agreement allows both Pulsenmore and Clalit to market Pulsenmore FC directly to patients.

Pulsenmore previously reported results in June 2025 from a controlled clinical study at Beilinson Medical Center that demonstrated a strong safety profile, with high concordance between at-home measurements and in-clinic assessments.  

Fertility treatment often requires frequent in-clinic transvaginal ultrasound scans and repeated visits that disrupt daily life. Pulsenmore FC is designed to offer another way, enabling eligible patients to complete follicular monitoring scans from home using the Pulsenmore FC, a patient-operated ultrasound device, and step-by-step guidance in a mobile app. Scan data are transmitted securely to the Beilinson NEXT care team for remote interpretation and clinical oversight, supporting monitoring of follicle development and endometrial thickness for accurate timing of key moments in treatment, including the trigger injection and egg retrieval, while helping reduce the need for repeated in-clinic visits during IVF and fertility preservation cycles.